Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| PDL BIOPHARMA, INC.PDLI · Entity 143144 | Director | June 20, 2019 | June 25, 2019 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Chief Medical Officer | February 26, 2021 | February 26, 2021 |
| Tonix Pharmaceuticals Holding Corp.TNXP · Entity 6169 | Director | June 12, 2018 | June 13, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
PDL BIOPHARMA, INC.
Report date June 20, 2019 · Filed June 25, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.00 · Expires 2029-06-19 | Direct | 126,050 |
Reported balance
After 2019-06-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-20 · Grant · Acquired 126,050 · Balance 126,050 F1: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date.
Protagonist Therapeutics, Inc
Report date February 26, 2021 · Filed February 26, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,000 |
Reported balance
After 2021-02-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-02-26 · Grant · Acquired 12,000 · Balance 14,000 F1: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024. F2: Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2020. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $23.57 · Expires 2031-02-25 | Direct | 90,000 |
Reported balance
After 2021-02-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-02-26 · Grant · Acquired 90,000 · Balance 90,000 F3: The stock option vests in 48 equal monthly installments following the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024.
F2: Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2020.
F3: The stock option vests in 48 equal monthly installments following the date of grant.
Tonix Pharmaceuticals Holding Corp.
Report date June 12, 2018 · Filed June 13, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.25 · Expires 2028-06-12 | Direct | 20,000 |
Reported balance
After 2018-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 20,000 · Balance 20,000 F1: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2021 Filed Feb 26, 2021 23:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 90,000 | $0.00 Strike: $23.57 | $0.00 |
DisclosureSEC source: 0001209191-21-014984 · doc4.xml · derivative · entry 2 Saks Samuel R · CIK 0001365615 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-25 F3 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 26, 2021 Filed Feb 26, 2021 23:35 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-014984 · doc4.xml · nonDerivative · entry 1 Saks Samuel R · CIK 0001365615 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · shares: Represents grant of restricted stock units payable solely in common stock that will become fully vested on February 26, 2024. F2 · balance_after: Includes 2,000 shares acquired by the Reporting Person under the Issuer's 2016 Employee Stock Purchase Plan on September 9, 2020. Read SEC document |
| February 28, 2020 Filed Feb 28, 2020 22:49 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 85,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-20-014100 · doc4.xml · derivative · entry 1 Saks Samuel R · CIK 0001365615 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2030-02-27 F1 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| June 20, 2019 Filed Jun 25, 2019 01:40 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantStock Option (right to buy) · Derivative | 126,050 | $3.00 Strike: $3.00 | $378,150.00 |
DisclosureSEC source: 0000882104-19-000073 · wf-form4_156142682613892.xml · derivative · entry 1 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 126,050 Underlying: Common stock · 126,050 shares Expires 2029-06-19 F1 · derivative.exercise_date: The stock options shall vest on a monthly basis pro rata over the twelve (12) months following the grant date, provided that the recipient's continuous service has not terminated prior to the applicable vesting date. Read SEC document |
| May 15, 2019 Filed May 16, 2019 22:43 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $10.80 | $0.00 |
DisclosureSEC source: 0001209191-19-030616 · doc4.xml · derivative · entry 1 Saks Samuel R · CIK 0001365615 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2029-05-14 F1 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:32 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.02 | $0.00 |
DisclosureSEC source: 0001209191-19-015930 · doc4.xml · derivative · entry 2 Saks Samuel R · CIK 0001365615 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2029-02-27 F2 · derivative.exercise_date: The stock option vests in 48 equal monthly installments following the date of grant. Read SEC document |
| February 28, 2019 Filed Mar 4, 2019 23:32 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015930 · doc4.xml · nonDerivative · entry 1 Saks Samuel R · CIK 0001365615 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,500 F1 · shares: Represents grant of the restricted stock units payable solely in common stock that vest in equal annual installments over four years from the grant date. Read SEC document |
| June 12, 2018 Filed Jun 13, 2018 21:14 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.25 | $0.00 |
DisclosureSEC source: 0001615774-18-005229 · s110810_form4.xml · derivative · entry 1 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2028-06-12 F1 · price: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. F1 · derivative.exercise_date: The option was granted pursuant to the Issuer's 2018 Stock Incentive Plan. Read SEC document |
| June 08, 2018 Filed Jun 12, 2018 20:28 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 54,348 | $2.76 | $150,000.48 |
DisclosureSEC source: 0000882104-18-000064 · wf-form4_152883529550586.xml · nonDerivative · entry 1 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,190 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. Read SEC document |
| May 31, 2018 Filed May 31, 2018 22:29 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $7.28 | $0.00 |
DisclosureSEC source: 0001209191-18-034472 · doc4.xml · derivative · entry 1 Saks Samuel R · CIK 0001365615 · Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-05-30 F1 · derivative.exercise_date: The option vests over a four-year period, with 1/4th of the shares subject to the option vesting on the one year anniversary of the vesting commencement date of May 21, 2018, and 1/36th of the remaining shares subject to the option vesting each month. Read SEC document |
| June 20, 2017 Filed Jun 21, 2017 21:00 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | GrantStock Option · Derivative | 20,000 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001615774-17-003294 · s106633_form4.xml · derivative · entry 1 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2027-06-20 F1 · price: The option was granted pursuant to the Issuer's 2017 Stock Incentive Plan. Read SEC document |
| June 09, 2017 Filed Jun 13, 2017 00:20 UTC | PDL BIOPHARMA, INC. PDLI · Entity 143144 | GrantCommon stock | 60,729 | $2.47 | $150,000.63 |
DisclosureSEC source: 0000882104-17-000066 · wf-form4_149731318782655.xml · nonDerivative · entry 1 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,842 F1 · shares: The grant will cliff-vest on the first anniversary of the date of grant so long as the grant recipient continues to serve on the Board of Directors of PDL BioPharma, Inc. During the one-year vesting period, the grant recipient will have the right to vote the shares and receive any dividends and other distributions paid, except that dividends and other distributions will be accumulated and will vest and be paid, with interest, on the earlier of the same vesting conditions as the original award or March 15th of the year following the payment of such dividend or distribution to all stockholders. Read SEC document |
| May 27, 2017 Filed Mar 9, 2018 20:36 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001756 · s109300_form4.xml · derivative · entry 4 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F2 · derivative.expiration_date: On May 27, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| May 27, 2017 Filed Mar 9, 2018 20:36 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001756 · s109300_form4.xml · nonDerivative · entry 1 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 09, 2017 Filed Mar 9, 2018 20:36 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001756 · s109300_form4.xml · derivative · entry 5 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. F3 · derivative.expiration_date: On February 9, 2016, the reporting person was granted 750 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 09, 2017 Filed Mar 9, 2018 20:36 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 750 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001756 · s109300_form4.xml · nonDerivative · entry 2 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 20:36 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionRestricted Stock Units · Derivative | 650 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001756 · s109300_form4.xml · derivative · entry 6 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. F4 · derivative.expiration_date: On February 25, 2015, the reporting person was granted 600 restricted stock units, vesting in on the first anniversary of the grant date. Read SEC document |
| February 25, 2016 Filed Mar 9, 2018 20:36 UTC | Tonix Pharmaceuticals Holding Corp. TNXP · Entity 6169 | Exercise / conversionCommon Stock, $0.001 par value | 600 | $0.00 | $0.00 |
DisclosureSEC source: 0001615774-18-001756 · s109300_form4.xml · nonDerivative · entry 3 Saks Samuel R · CIK 0001365615 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,855 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.